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Early involvement of cellular stress 
and inflammatory signals in the 
pathogenesis of tubulointerstitial 
kidney disease due to UMOD 
mutations
Matteo Trudu1, Celine Schaeffer1, Michela Riba2, Masami Ikehata3,4, Paola Brambilla5, 
Piergiorgio Messa3,4, Filippo Martinelli-Boneschi5, Maria Pia Rastaldi3 & Luca Rampoldi  1
Autosomal dominant tubulointerstitial kidney disease (ADTKD) is an inherited disorder that causes 
progressive kidney damage and renal failure. Mutations in the UMOD gene, encoding uromodulin, lead 
to ADTKD-UMOD related. Uromodulin is a GPI-anchored protein exclusively produced by epithelial cells 
of the thick ascending limb of Henle’s loop. It is released in the tubular lumen after proteolytic cleavage 
and represents the most abundant protein in human urine in physiological condition. We previously 
generated and characterized a transgenic mouse model expressing mutant uromodulin (TgUmodC147W) 
that recapitulates the main features of ATDKD-UMOD. While several studies clearly demonstrated that 
mutated uromodulin accumulates in endoplasmic reticulum, the mechanisms that lead to renal damage 
are not fully understood. In our work, we used kidney transcriptional profiling to identify early events of 
pathogenesis in the kidneys of TgUmodC147W mice. Our results demonstrate up-regulation of inflammation 
and fibrosis and down-regulation of lipid metabolism in young TgUmodC147W mice, before any functional 
or histological evidence of kidney damage. We also show that pro-inflammatory signals precede fibrosis 
onset and are already present in the first week after birth. Early induction of inflammation is likely 
relevant for ADTKD-UMOD pathogenesis and related pathways can be envisaged as possible novel 
targets for therapeutic intervention.
Tubulointerstitial kidney diseases occur with a diverse array of causes, including genetic disorders, and constitute 
an important cause of chronic kidney disease (CKD). Inherited renal tubulointerstitial disorders include auto-
somal dominant tubulointerstitial kidney disease (ADTKD), characterised by interstitial fibrosis with tubular 
atrophy and dilation, and thickening and lamellation of tubular basal membranes1. Five ADTKD genes have been 
identified so far: UMOD (16p12)2, MUC1 (mucin 1, 1q21)3, HNF1B (HNF1beta, 17q12)4, REN (renin, 1q32)5 and 
SEC 61A1 (Sec 61 translocon alpha 1 subunit, 3q21)6. ADTKD-UMOD patients reach end-stage renal disease 
between 20 and 70 years of age. Currently, no specific treatment can be offered other than renal replacement 
therapy. The UMOD gene encodes uromodulin, the most abundant protein in human urine in physiological 
condition. Uromodulin is a highly glycosylated protein that is exclusively produced by epithelial cells lining the 
thick ascending limb of Henle’s loop (TAL) and released in the tubular lumen after cleavage mediated by the ser-
ine protease hepsin7. To date, over 100 UMOD mutations have been described. ADTKD-UMOD (MIM 162000, 
603860, 191845) is typically characterised by decreased fractional excretion of urate, causing hyperuricemia 
and often gout8. The biological function of uromodulin is still not fully understood. Studies in Umod knock-out 
mice showed that it has a protective role against urinary tract infections and calcium oxalate crystals damage9, 10. 
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Uromodulin was shown to regulate ion transport in the TAL11, 12. It has been proposed to act as a kidney-specific 
damage associated molecular pattern that can activate interstitial dendritic cells when released in the interstit-
ium13, 14. Also, uromodulin was shown to protect renal tubules from ischemia reperfusion injury15.
Several genome-wide association studies identified common variants in the UMOD gene promoter associated 
with increased risk of developing hypertension and CKD16, 17 by having an effect on UMOD expression and con-
sequent urinary protein levels12, 18.
We and others demonstrated that UMOD mutations lead to defective trafficking to the plasma membrane 
and endoplasmic reticulum (ER) retention of mutant uromodulin19, 20. This is consistent with findings in patient 
renal biopsies, typically showing the presence of large intracellular aggregates of uromodulin in TAL epithelial 
cells and abnormal expansion of ER stacks21 and with reduced uromodulin levels in patient urines22–24. In our 
laboratory, we generated a transgenic mouse expressing C147W mutant uromodulin (TgUmodC147W) (correspond-
ing to patient mutation C148W)25. TgUmodC147W mice specifically show progressive signs of renal damage, i.e. 
tubulointerstitial fibrosis with inflammatory cell infiltration and tubule dilation, urinary concentrating defect 
and renal failure. These features are associated with early ER retention and aggregation of uromodulin. A similar 
phenotype was described in three additional mouse models, carrying different Umod missense mutations (A227T, 
C93F, C125R)26–28. Altogether, studies in mouse models clearly establish a main gain-of-function effect of uro-
modulin mutations, also supported by the fact that Umod knock-out mice do not develop histological features of 
ADTKD-UMOD29. Since signs of renal failure and urine concentrating defect have been reported in mice lacking 
uromodulin30, we cannot exclude a partial loss-of-function component, possibly due to sequestration of wild type 
uromodulin in aggregates.
The cellular pathways leading to the clinical manifestations of the disease are currently unknown. To gain 
insight into ADTKD-UMOD pathophysiology, and in particular to study the early events that precede signs of 
renal disease, we carried out transcriptional profiling of kidneys from young, pre-symptomatic TgUmodC147W mice. 
Our results show early induction of inflammatory signals that precede fibrotic pathways and renal damage, and 
that likely play a key role in the disease onset.
Results
Transcriptional profiling of kidneys from TgUmodC147W and TgUmodwt mice. We previously showed 
that TgUmodC147W mice already display mild tubulointerstitial damage at 3 months of age, and that renal dam-
age progresses into severe interstitial fibrosis, inflammatory cell infiltrate, tubular atrophy and renal failure by 6 
months. Up to this time point TgUmodwt mice, i.e. transgenic mice for wild type uromodulin serving as an expres-
sion-matched control, were similar to control, non-transgenic mice25.
Aiming at identifying early events triggered by the expression of mutant uromodulin, we performed tran-
scriptional profiling of kidneys from 1 month-old TgUmodC147W and TgUmodwt mice (males and females). At this age 
mutant uromodulin is already strongly accumulating in the ER of TAL cells in the kidneys of TgUmodC147W mice 
(Supplementary Figure 1), while no renal damage can be observed at the histological level, except for an increase 
in the number of tubular casts formation (Fig. 1 and Supplementary Figure 2). We also carried out transcrip-
tional profile analysis on kidneys from female mice at a later time point (2 month-old), with the goal of identify-
ing pathways related to the progression of the disease. In kidneys from 1 month-old mice we obtained positive 
hybridisation signal for 19,026 (males) and 18,523 (females) probes, corresponding to 13,662 and 13,357 genes 
expressed in males and females respectively. At 2 months of age 18,302 probes, corresponding to 13,187 genes, 
were expressed. Multivariate analyses performed on expressed genes using hierarchical clustering and Principal 
Component Analysis (PCA) allowed the separation of TgUmodC147W sample groups from TgUmodwt ones (Fig. 2). 
This demonstrates that mutant uromodulin expression is inducing significant transcriptional changes in the kid-
ney at a time point in which renal structure is still preserved. Differential expression analysis was assessed in each 
of the 3 age- and sex-matched comparisons between TgUmodC147W and TgUmodwt mice, using a cut-off adjusted P 
value 0.05 and fold change 2. The number of genes up-regulated in 1 month-old TgUmodC147W mice were 92 and 68 
while the down-regulated ones were 179 and 89 in males and females respectively. In the 2 month-old TgUmodC147W 
mice we found 41 up-regulated and 15 down-regulated genes (Table 1). We validated results from the microar-
ray analysis by real-time RT-qPCR, selecting genes that were differentially expressed (adjusted P < 0.05) in all 
comparisons. In particular, we chose transcripts highly (fold change >  ± 2; Col1a1 and Slc25a17), moderately 
(fold change ~ ±1.5; Ntn4 and Slc13a3) or only slightly (fold change ~ +1.1; Panx1) up- or down-regulated in 
TgUmodC147W mice. Differential expression was confirmed for all analysed genes (Table 2).
Pathways related to inflammation, fibrosis and lipid metabolism are altered in the kidneys 
of 1 month old TgUmodC147W. We carried out pathway analysis on transcriptional data from 1 month-old 
transgenic mice by combining results from GSEA (Gene Set Enrichment Analysis) (FDR or q value < 0.05) and 
DAVID functional annotation tools.
Clustering analysis with GSEA using Kyoto Encyclopedia of Genes and Genomes (KEGG) database shows 
up-regulation of pathways related to inflammation and fibrosis, and a decrease of fatty acid and amino-acid 
metabolism (Tables 3 and 4). Consistently, clustering of differentially expressed genes according to their cellular 
localization shows up-regulation of components of the extracellular matrix and down-regulation of peroxisomal 
and mitochondrial genes (data not shown). Very similar results were obtained performing analysis with DAVID 
(data not shown). Identification of fibrosis and inflammation as the most represented signatures in 1 month-old 
TgUmodC147W mice is interesting, as no clear signs of renal fibrosis or inflammation were detected at the histological 
level in these mice (Fig. 1). In order to confirm up-regulation of inflammatory pathways we assessed by RT-qPCR 
the expression of chemokines (i.e. Ccl5, Ccl12 and Ccl19) that are up-regulated at later time points in TgUmodC147W 
mice (Supplementary Figure 3). Interestingly, transcripts of these chemokines are indeed already increased in the 
kidneys of mutant mice at 1 month of age (Fig. 3). Also, we confirmed by RT-qPCR the increased expression of 
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genes involved in fibrosis (i.e. Tgfb1, Vim, Col6a1 and Acta2) and the reduced expression of genes belonging to 
lipid metabolism pathways (i.e. Acox3, Ehhadh and Cyp4b1) (Fig. 3).
We further characterised inflammation in the kidneys of 1 month-old TgUmodC147W mice by assessing the 
expression of markers of inflammatory cells by RT-qPCR analysis. While expression of Cd5 (T cells) and Cd19 (B 
cells) was barely detectable (Cp > 35), we found robust expression of Cd45 (Ptprc) (common leukocyte marker), 
Cd68 (macrophage) and Cd15 (Fut4) (granulocyte). Relative expression analysis indicates increased infiltrating 
inflammatory cells, essentially macrophages, in the kidneys of TgUmodC147W mice (Fig. 4a). This was confirmed 
by immunohistochemistry analysis showing areas of focal macrophage invasion in the kidneys of 1 month-old 
TgUmodC147W mice (Fig. 4b).
Inflammatory pathways are associated with renal disease progression in TgUmodC147W 
mice. Pathway analysis on data from kidneys of 2 month-old mice confirmed findings on 1 month-old mice, 
with enrichment of genes related to inflammation and fibrosis (up-regulated) and to metabolism of fatty acids 
and amino acids (down-regulated) (data not shown). In order to identify pathways associated with disease pro-
gression, we compared transcriptional profiles derived from transgenic female mice at 1 and 2 months of age. 
We identified 477 genes that are significantly up- (196) or down-regulated (281) in TgUmodC147W mice at 2 months 
of age, regardless of their fold change, and that were not differentially expressed at 1 month of age. Pathway 
Figure 1. Representative images of kidneys from 1 month-old TgUmodC147W and TgUmodwt mice. 
Immunohistochemistry analysis for total uromodulin shows that the protein is mainly distributed at the 
apical membrane of TAL cells in TgUmodwt mice, while it is intracellularly enriched in TgUmodC147W mice (left 
panels, scale bar 100 µm). Representative images of kidney sections (right panels, PAS, scale bar 200 µm) and 
quantification of histological parameters (bottom) are shown. Data are expressed as mean ± s.d. (n = 9 TgUmodwt 
and 6 TgUmodC147W). TgUmodC147W mice show a relatively well preserved kidney structure. Only tubular casts, 
mostly uromodulin-positive (left panel, arrowhead) resulted to be increased. **P < 0.01 (Mann-Whitney test).
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enrichment analysis (clusterProfiler Bioconductor package, see Methods) identified up-regulated pathways 
related to inflammation and immune response, highlighting their growing activation along with disease pro-
gression. Noteworthy, pathways related to fatty acid and lipid metabolism were significantly enriched among 
down-regulated ones (Fig. 5). We also identified few genes showing opposite behaviour in 1 and 2 month-old 
mice: 5 genes that resulted significantly up-regulated in 1 month-old (A630097A12Rik, Adnp, Ren1, Spin, 
Ugt1a13) and significantly down-regulated in 2 month-old TgUmodC147W mice and 5 genes (4931408A02Rik, Gpx4, 
Igh-VJ558, LOC277193, Slc9a8) that showed opposite direction of age-related change. Future work will be needed 
to establish the significance of these findings for disease progression.
TAL stress and inflammatory signals represent an early event in ADTKD-UMOD. Our data 
showed induction of pathways related to inflammation and fibrosis in the kidneys of TgUmodC147W mice already at 
Figure 2. Multivariate Analysis and Principal Component Analysis (PCA) of experimental samples and groups. 
(a) The figure shows hierarchical clustering on the 150 genes showing the greatest inter-group variance among 
expressed genes in mice at 1 month of age (left panel) or in female mice only (right panel). (b) PCA based on the 
expression values of the 17,200 genes detected in the experimental samples (detection P value < 0.01 in at least 
one sample of an analysed series). A bi-dimensional visualization of the first two principal components is shown 
(PC1 accounted for 35.2% and PC2 for 25% of the variance among samples).
Genes up-regulated in 
TgUmodC147W
Genes down-regulated 
in TgUmodC147W
Males (1 m.o.) 92 179
Females (1 m.o.) 68 89
Females (2 m.o.) 41 15
Table 1. Genes differentially expressed in kidneys of TgUmodC147W mice relative to age- and sex-matched 
TgUmodwt mice. Only genes showing fold change >2 and Benjamini Hochberg adjusted P < 0.05 were considered 
as differentially expressed.
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1 month of age, demonstrating that expression of mutant uromodulin induces release of pro-inflammatory and 
pro-fibrotic signals well before the presence of any sign of renal damage at the histological level. To gain further 
insight into the potential role of inflammatory/fibrotic signals in the disease onset, we analysed kidneys of mice 8 
days postpartum (p8). Interestingly, ER retention of mutant uromodulin is already evident at this early time point 
(Fig. 6). In line with what observed at 1 month of age, evaluation of histological parameters reveals that kidneys 
of TgUmodC147W mice at p8 are similar to the ones of TgUmodwt mice (Supplementary Figure 4). We then analysed the 
transcript level of cytokines/chemokines, genes related to fibrosis and inflammatory cell markers in these kidneys. 
Interestingly, Ccl5 and Ccl12 genes were significantly increased in TgUmodC147W mice, while no differences were 
detected in expression of Ccl19 and of transcripts related to fibrosis or lipid metabolism (Fig. 7). Upregulation 
of chemokines in p8 kidneys was associated with higher expression of markers of inflammatory cells, indicating 
increased macrophage infiltrate (Fig. 8a–c). These results suggest that the induction of pro-inflammatory sig-
nals is likely one of the first events occurring in the kidneys of TgUmodC147W mice following mutant uromodulin 
expression.
We also checked the expression of Lcn2 (lipocalin 2 or Neutrophil gelatinase-associated lipocalin (NGAL)) 
and Hacvr1 (Hepatitis A virus receptor or Kidney injury molecule-1 (Kim1)) genes. Lcn2 and Havcr1 are 
well-established markers of distal and proximal tubule damage respectively that were found to be significantly 
up-regulated already at 1 month of age in the transcriptome analysis of TgUmodC147W kidneys. At p8 we detected 
both at transcript and protein level significant up-regulation of Lcn2 while expression of Kim1 was not different 
in TgUmodC147W mice (Fig. 9a,c). These results suggest that renal damage occurs in the distal tubules first, where 
uromodulin is expressed and is then spread to neighbouring proximal tubules. Data from microarray analysis 
show up-regulation of Atf3 transcript. ATF3 is a transcription repressor that was shown to play a protective role in 
the kidney after ischemia/reperfusion injury through anti-inflammatory and anti-apoptotic effects in renal tubu-
lar epithelial cells31. It can be induced by a large variety of stresses, including ER stress, cytokine, genotoxic and 
cytotoxic agents32. Interestingly, we found increased expression of Atf3 at transcript and protein level (Fig. 9a,b), 
specifically in TAL nuclei at p8 (Supplementary Figure 5). These data suggest early induction of cellular stress in 
TAL cells of TgUmodC147W mice.
Discussion
In this study, we aimed at identifying early renal pathways triggered by expression of mutant uromodulin in a 
mouse model of ADTKD-UMOD. Our results derived from transcriptional profiling of kidneys from young adult 
mice show that inflammation and fibrosis are two of the most up-regulated pathways, while down-regulated 
ones are mostly related to lipid and amino acid metabolism. In line with this, clustering of DEGs according to 
their localization indicates up-regulation of components of the extracellular matrix and down-regulation of per-
oxisomal and mitochondrial genes. Moreover, the comparison of transcriptional data from 1 and 2 month-old 
TgUmodC147W mice indicate that inflammatory pathways may play a role in the progression of the disease.
Deregulation of some of the identified pathways has already been observed in other models of renal damage. 
By using a genetic model of nephronophthisis, i.e. mice lacking Glis2, it was shown that tubulointerstitial infil-
trating cells and fibrosis are already present in kidneys of young animals33. Also, in a genetic model of Alport syn-
drome tubulointerstitial nephritis associated with presence of inflammatory cells is one of the major histological 
features34. Fibrotic pathways have also been shown to be up-regulated at 3 weeks of age in a rat model of poly-
cystic kidney disease35. More recently, down-regulation of amino-acid and lipid metabolism has been associated 
with renal damage progression in humans and in mouse models of tubulointerstitial fibrosis36. Markers of lipid 
metabolism were indeed strongly reduced in fibrotic human kidneys. Moreover, restoring fatty acid metabolism 
by genetic or pharmacological methods protected mice from tubulointerstitial fibrosis36. Interestingly, also reduc-
tion of mitochondrial activity has been linked to kidney diseases37. Moreover, decreased number of functional 
peroxisomes was shown to worsen tubulointerstitial damage38. Overall, these data suggest that the main pathways 
that are dysregulated in kidneys of TgUmodC147W mice may reflect common features of chronic kidney disease onset 
and progression.
By using two different mouse lines carrying Umod mutations (UmodC93F, UmodA227T) induced by 
N-ethyl-N-nitrosourea (ENU), Kemter et al. showed that inflammation could play a role in models of 
ADTKD-UMOD, via activation of NF-kB pathway in TAL segments39. Consistently, pathway analysis of tran-
scriptome data from female TgUmodC147W mice shows up-regulation of NF-kB pathway (Biocarta database, data 
not shown), suggesting that this pathway has a role also in TgUmodC147W mice. Moreover, Horsch et al. performed 
transcriptional profiling of kidneys from young-adult UmodA227T mice (17 weeks, mild disease model) and aged 
Gene
Males (1 m.o.) Females (1 m.o.) Females (2 m.o.)
RT-qPCR Microarray RT-qPCR Microarray RT-qPCR Microarray
Col1a1 1.79** 2.09§§§ 1.73** 2.20§§§ 2.65*** 2.53§§§
Ntn4 1.59** 1.48§§§ 1.17 1.32§§ 1.52* 1.46§§
Panx1 2.30** 1.16§ 2.07*** 1.22§ 2.16*** 1.39§§§
Slc13a3 0.48* 0.67§§§ 0.56** 0.68§§ 0.56* 0.71§§
Slc25a17 0.47*** 0.53§§§ 0.34*** 0.46§§§ 0.35* 0.41§§§
Table 2. Fold change of kidney gene expression in TgUmodC147W mice relative to age- and sex-matched TgUmodwt. 
*P < 0.05; **P < 0.01; ***P < 0.001 (unpaired t-test). §P < 0.05; §§P < 0.01; §§§P < 0.001 (Benjamini Hochberg 
adjusted).
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UmodC93F mice (38 weeks, advanced disease model). Overall, their analysis led to the identification of 104 and 54 
DEGs at 17 and 38 weeks respectively, associated with cancer, cell proliferation, necrosis, inflammation, lipid and 
protein metabolism. About 15–30% of DEGs are also differentially expressed in TgUmodC147W mice. Discrepancies 
in the number/type of DEGs may be due to several differences, as genetic model (ENU mutant versus transgenic), 
Up-regulated pathway FDR
Number of 
genes Contributing genes
ECM RECEPTOR INTERACTION 0 31/55 (84)
Itgb1, Sdc3, Col1a2, Sdc1, Itga3, Lama5, Tnxb, Lamb2, Sv2a, Vwf, Sdc2, 
Lamc1, Itga11, Agrn, Lama2, Tnn, Col4a1, Hspg2, Col6a2, Thbs2, Col4a2, 
Col6a1, Fn1, Itgb4, Lamc2, Col6a3, Cd44, Col5a1, Col3a1, Tnc, Col1a1
FOCAL ADHESION 0 51/133 (201)
Pdgfa, Pdgfrb, Met, Itgb1, Pik3r3, Col1a2, Itga3, Lama5, Tln2, Birc2, Ppp1ca, 
Tnxb, Lamb2, Pdgfb, Vwf, Ptk2, Vegfc, Ilk, Cav2, Ppp1cb, Akt3, Shc1, Actn4, 
Lamc1, Itga11, Cav1, Figf, Lama2, Tnn, Col4a1, Actb, Vcl, Col6a2, Capn2, 
Thbs2, Col4a2, Col6a1, Mylk, Pdgfra, Fn1, Itgb4, Flnc, Lamc2, Flna, Col6a3, 
Col5a1, Actn1, Col3a1, Myl9, Tnc, Col1a1
DNA REPLICATION 0 17/29 (36) Pola2, Rfc1, Rfc4, Pold2, Rfc3, Rfc5, Rpa1, Pold1, Rpa2, Mcm7, Fen1, Pole, Lig1, Mcm2, Mcm4, Mcm6, Mcm5
REGULATION OF ACTIN 
CYTOSKELETON 0.001 60/133 (216)
Actn2, Was, Fgfr2, Arhgef1, Nckap1, Arpc2, Rac1, Vav3, Rac2, Mapk1, Rock2, 
Fgfr1, Itga1, Arpc1a, Pfn2, Rac3, Abi2, Arpc5, Tmsb4x, Pdgfa, Pdgfrb, Limk1, 
Itgb1, Pik3r3, Pip5k1a, Pip4k2a, Itga3, Nras, Myh10, Ppp1ca, Wasf2, Pdgfb, 
Mras, Ptk2, Limk2, Pfn1, Tiam1, Ppp1cb, Fgf10, Actn4, Arhgef4, Itga11, 
Iqgap1, Rras, Nckap1l, Myh9, Arpc1b, Msn, Actb, Vcl, Scin, Gsn, Mylk, Pdgfra, 
Fn1, Itgb4, Actn1, Myl9, Cd14, F2r
LEUKOCYTETRANSENDOTHELIAL 
MIGRATION 0.001 38/72 (118)
Cldn23, Esam, Actn2, Ctnnb1, Mapk12, Rac1, Mapk11, Vav3, Rac2, Rock2, 
Cldn15, Cdh5, Gnai2, Mmp9, Ptpn11, Itgb1, Cldn7, Pik3r3, Pecam1, Cldn6, 
Ptk2, Ctnna1, Actn4, Ncf4, Mapk13, Msn, Actb, Vcl, Cldn19, Icam1, Cldn4, 
Cldn16, Cxcl12, Thy1, Mmp2, Actn1, Vcam1, Myl9
GAP JUNCTION 0.001 19/36 (90)
Adcy2, Tjp1, Mapk1, Adcy4, Plcb3, Gnai2, Gnas, Pdgfa, Pdgfrb, Csnk1d, Nras, 
Adcy1, Pdgfb, Prkx, Prkg1, Gja1, Tubb6, Gucy1a3, Itpr3, Htr2b, Tuba1b, 
Pdgfra, Tuba1a, Tubb2b
PATHOGENIC ESCHERICHIA COLI 
INFECTION 0.001 19/36 (59)
Was, Ctnnb1, Ncl, Arpc2, Rock2, Arpc1a, Cdh1, Tlr4, Arpc5, Itgb1, Hcls1, 
Arpc1b, Actb, Tubb6, Tuba1b, Tuba1a, Krt18, Cd14, Tubb2b
CYTOKINE CYTOKINE RECEPTOR 
INTERACTION 0.002 28/81 (267)
Cx3cr1, Pdgfa, Pdgfrb, Met, Il11, Tgfb3, Ifngr1, Pdgfb, Tnfrsf1a, Vegfc, Tgfbr2, 
Ccl7, Ccl4, Ccl19, Bmpr1b, Figf, Ccl5, Cxcl14, Il28ra, Tnfsf13b, Tnfrsf21, Cxcl1, 
Pdgfra, Cxcl12, Tnfrsf12a, Cx3cl1, Inhba, Osmr
RIBOSOME 0.002 47/55 (88)
Uba52, Rpl4, Rpl34, Rpl22, Rpl26, Rps29, Rpl19, Rpl18a, Rps27a, Rpl35, 
Rps10, Rps3a, Rps15, Rpl32, Rpl28, Rpl7a, Rps24, Rpl37, Rps19, Rps2, Rps21, 
Rpl9, Rpl13a, Rps7, Rpl27a, Rpl27, Rps5, Rpl10a, Rps15a, Rpl36al, Rpl24, 
Rplp0, Rpl30, Rps12, Rps13, Rps8, Rpl39, Rpl3, Rpl18, Rpl12, Rps9, Rps16, 
Rplp2, Rps3, Rpl36a, Rpl22l1, Rpl31
CELL CYCLE 0.010 48/80 (128)
Zbtb17, Cdkn1c, Anapc2, Mdm2, Cul1, Ccnd3, Ywhaz, Smad2, Cdc16, Stag1, 
Ywhag, Tgfb1, E2f3, Ywhab, Cdkn2d, Hdac2, Smc3, Smc1a, Gadd45g, Fzr1, 
Rbl1, Mad2l2, Anapc5, Ywhae, Skp2, Gadd45b, Tgfb3, E2f2, Smad3, Cdk4, 
Cdk2, Tfdp1, Dbf4, Plk1, Cdc20, Ccnb1, Mad2l1, Ywhah, Mcm7, Bub1b, Cdc6, 
Mcm2, Cdkn2b, Cdc7, Mcm4, E2f1, Mcm6, Mcm5
Down-regulated pathway FDR Number of genes Contributing genes
GLYCINE SERINE AND THREONINE 
METABOLISM 0 15/23 (31)
Shmt1, Amt, Gatm, Gamt, Srr, Psat1, Shmt2, Gldc, Glyctk, Pipox, Agxt2, 
Sardh, Gnmt, Dmgdh, Cbs
PEROXISOME 0 31/61 (78)
Gnpat, Mlycd, Pex26, Nudt19, Pex11a, Mpv17, Acsl1, Dhrs4, Pex7, Pex3, 
Acot8, Pxmp2, Pex5, Pex6, Scp2, Pxmp4, Gstk1, Hmgcl, Acox3, Sod1, Cat, Ddo, 
Prdx5, Abcd4, Pipox, Pex1, Pecr, Ephx2, Hacl1, Ehhadh, Slc25a17
BUTANOATE METABOLISM 0 17/21 (34) Aldh3a2, Bdh2, Acsm5, Hmgcs2, Aldh2, Oxct1, Aldh1b1, Acads, Acat1, Hmgcl, L2hgdh, Aldh5a1, Abat, Bdh1, Ehhadh, Aacs, Acsm3
VALINE LEUCINE AND 
ISOLEUCINE DEGRADATION 0 19/33 (44)
Hsd17b10, Aldh6a1, Aldh3a2, Mccc2, Bcat1, Hmgcs2, Pccb, Aldh2, Mccc1, 
Oxct1, Aldh1b1, Acads, Acat1, Hmgcl, Abat, Ivd, Bckdha, Acadm, Ehhadh
PYRUVATE METABOLISM 0.006 11/25 (40) Aldh2, Hagh, Grhpr, Aldh1b1, Mdh1, Acat1, Acss2, Pck1, Pklr, Acot12, Ldhd
TYROSINE METABOLISM 0.010 8/18 (42) Aldh3b1, Fah, Hgd, Hemk1, Nat6, Comt, Hpd, Ddc
PROPANOATE METABOLISM 0.011 13/20 (33) Ehhadh, Acadm, Abat, Acss2, Acat1, Aldh1b1, Suclg2, Aldh2, Suclg1, Pccb, Mlycd, Aldh3a2, Aldh6a1
PPAR SIGNALING PATHWAY 0.018 23/41 (69)
Apoc3, Ehhadh, Lpl, Cyp27a1, Aqp7, Ppard, Acadm, Nr1h3, Acox3, Pck1, 
Ppara, Fads2, Scp2, Rxra, Slc27a1, Acsl1, Acadl, Hmgcs2, Adipoq, Pdpk1, Cpt2, 
Rxrb, Dbi
DRUG METABOLISM 
CYTOCHROME P450 0.020 15/29 (72)
Cyp2e1, Fmo4, Fmo1, Gstk1, Gsta3, Gstm1, Gstt1, Gsto2, Gstm5, Aldh3b1, 
Gstt2, Gstp1, Mgst3, Gsta2, Fmo5
SELENOAMINO ACID 
METABOLISM 0.038 5/20 (26) Cbs, Ahcy, Hemk1, Scly, Papss2
Table 3. List of the top 10 KEGG pathways up- or down-regulated in 1 month-old female TgUmodC147W mice 
relative to age- and sex-matched TgUmodwt. FDR, False Discovery Rate. Number of genes, A/B (C): A, number of 
genes contributing to pathway enrichment; B, number of genes from the KEGG pathway expressed in analysed 
experimental groups; C, total number of genes listed in the KEGG pathway.
www.nature.com/scientificreports/
7SCIENtIFIC REPoRTs | 7: 7383  | DOI:10.1038/s41598-017-07804-6
Umod mutations, mouse strain, microarray platform (in-house produced versus commercially available, covering 
17,346 genes and 48,804 transcripts respectively). Despite such differences, it is interesting to note that some of 
the main pathways identified in our study, as inflammation and lipid metabolism, were also detected in the study 
by Horsch et al. It is also of note that, similarly to what we observed, also in ENU models the number of DEGs 
decreases with disease progression.
Our data suggest that inflammation has relevance in the onset and progression of the renal disease in 
TgUmodC147W mice as we identified increased levels of chemokines in kidneys of mutant mice already at p8. At this 
time point, we were also able to find presence of infiltrating cells. Real time analyses showed that inflammatory 
cells are mainly represented by cells of the innate immunity type (i.e. macrophages) instead of cells of the adap-
tive immunity (i.e. T and B cells). This is in line with what observed in an Alport syndrome mouse model, that 
Up-regulated pathway FDR
Number of 
genes Contributing genes
FOCAL ADHESION 0 58/138 (201)
Pik3r1, Ptk2, Prkca, Crk, Col1a2, Ppp1r12a, Itga11, Zyx, Ilk, Tnxb, 
Igf1, Vwf, Itga10, Itga3, Vav3, Itga9, Egf, Itga5, Vcl, Flnc, Akt3, Shc1, 
Capn2, Actn4, Itgb6, Vegfc, Tnn, Jun, Col4a2, Pdgfrb, Actb, Ccnd2, 
Col4a1, Pdgfb, Lamb2, Thbs1, Lamc1, Flna, Itgb4, Cav1, Lamc2, 
Mylk, Figf, Actn1, Pik3r3, Lama2, Thbs2, Spp1, Col3a1, Col6a3, 
Col6a2, Col6a1, Pdgfra, Col5a1, Fn1, Col1a1, Tnc, Myl9
ECM RECEPTOR INTERACTION 0 34/57 (84)
Vtn, Col1a2, Cd47, Itga11, Sv2a, Tnxb, Vwf, Itga10, Itga3, Itga9, 
Agrn, Itga5, Itgb6, Tnn, Col4a2, Cd44, Col4a1, Lamb2, Thbs1, Hspg2, 
Lamc1, Itgb4, Lamc2, Lama2, Thbs2, Spp1, Col3a1, Col6a3, Col6a2, 
Col6a1, Col5a1, Fn1, Col1a1, Tnc
RIBOSOME 0.001 37/52 (88)
Rpl39, Rpl23, Rps19, Rpl36a, Rps21, Rpl9, Rpl3, Rpl27a, Rpl19, 
Rps11, Rpl32, Rplp2, Rps5, Rps2, Rps10, Rpl38, Rpl7a, Rpl22, Rpl28, 
Rpl35, Rps15a, Rpl30, Rpl37, Rps12, Rps15, Rps8, Rpl18, Rpl18a, 
Rpl34, Rpl26, Rps6, Rps26, Rps24, Rps9, Rpl31, Rps3, Rps16
DILATED CARDIOMYOPATHY 0.001 22/48 (92)
Prkx, Tgfb3, Itga11, Tgfb1, Igf1, Itga10, Itga3, Itga9, Gnas, Atp2a2, 
Itga5, Itgb6, Actb, Adcy4, Cacnb3, Adcy6, Itgb4, Slc8a1, Tpm2, Tpm4, 
Lama2, Tpm1
GAP JUNCTION 0.002 23/51 (90)
Prkca, Nras, Prkx, Csnk1d, Gja1, Gnai2, Tuba1b, Itpr2, Egf, Gnas, 
Gucy1b3, Prkg1, Pdgfrb, Tubb6, Adcy4, Pdgfb, Adcy6, Itpr3, Htr2b, 
Gucy1a3, Tuba1a, Pdgfra, Tubb2b
LEUKOCYTE TRANSENDOTHELIAL 
MIGRATION 0.002 31/73 (118)
Ptpn11, Mapk12, Ctnna1, Pik3r1, Ptk2, Prkca, Icam1, Cxcl12, Rassf5, 
Cxcr4, Cldn15, Pecam1, Gnai2, Vav3, Plcg2, Msn, Esam, Vcl, Cdh5, 
Actn4, Actb, Cldn19, Thy1, Actn1, Pik3r3, Cldn16, Cldn4, Vcam1, 
Cldn10, Mmp2, Myl9
ARRHYTHMOGENIC RIGHT 
VENTRICULAR CARDIOMYOPATHY 
ARVC
0.009 24/40 (76)
Itgb1, Dag1, Emd, Itgb5, Cacna2d1, Jup, Ctnna1, Itga11, Gja1, Itga10, 
Itga3, Itga9, Atp2a2, Itga5, Actn4, Itgb6, Dsp, Actb, Cacnb3, Itgb4, 
Slc8a1, Actn1, Lama2, Dsg2
HYPERTROPHIC CARDIOMYOPATHY 
HCM 0.015 18/45 (85)
Tgfb3, Itga11, Tgfb1, Igf1, Itga10, Itga3, Itga9, Atp2a2, Itga5, Itgb6, 
Actb, Cacnb3, Itgb4, Slc8a1, Tpm2, Tpm4, Lama2, Tpm1
VASCULAR SMOOTH MUSCLE 
CONTRACTION 0.019 24/63 (115)
Pla2g12a, Prkca, Ppp1r12a, Prkx, Pla2g4b, Itpr2, Gnas, Gucy1b3, 
Mrvi1, Myh11, Actg2, Ramp2, Prkg1, Ednra, Myl6, Adcy4, Adcy6, 
Itpr3, Mylk, Avpr1a, Adora2b, Gucy1a3, Myl9, Acta2
CARDIAC MUSCLE CONTRACTION 0.019 20/35 (80)
Cox6c, Cox6b1, Cox7b, Slc9a1, Tpm3, Atp1a2, Cacna2d1, Atp1b3, 
Cox7a2l, Cyc1, Cox7a1, Atp2a2, Cox6b2, Cacnb3, Atp1b2, Slc8a1, 
Tpm2, Fxyd2, Tpm4, Tpm1
Down-regulated pathway FDR Number of genes Contributing genes
PEROXISOME 0.001 36/63 (78)
Nudt19, Ephx2, Pecr, Ehhadh, Slc25a17, Acox3, Pipox, Nudt12, Far1, 
Agps, Cat, Acox1, Mlycd, Prdx5, Ddo, Abcd3, Amacr, Scp2, Dhrs4, 
Gnpat, Pxmp4, Slc27a2, Sod1, Pex3, Pex16, Gstk1, Pex2, Pex7, Abcd4, 
Pex14, Hmgcl, Crat, Pex11a, Prdx1, Mpv17, Sod2
BUTANOATE METABOLISM 0.001 11/21 (34) Acsm3, Aacs, Acat1, Ehhadh, Bdh1, Aldh3a2, Acsm5, Aldh5a1, L2hgdh, Acads, Abat
PROPANOATE METABOLISM 0.015 8/19 (33) Acat1, Ehhadh, Mlycd, Aldh3a2, Suclg2, Abat, Acss2, Aldh6a1
PYRUVATE METABOLISM 0.019 10/26 (40) Ldhd, Acot12, Acat1, Pck1, Aldh3a2, Acss2, Mdh1, Grhpr, Pklr, Dld
GLYCINE SERINE AND THREONINE 
METABOLISM 0.019 11/24 (31)
Cbs, Pipox, Shmt2, Gnmt, Sardh, Srr, Chdh, Dmgdh, Glyctk, Agxt2, 
Gamt
CYSTEINE AND METHIONINE 
METABOLISM 0.020 8/19 (34) Cbs, Ahcy, Mat2a, Mpst, Ahcyl1, Mtr, Trdmt1, Mat2b
SELENOAMINO_ACID_METABOLISM 0.020 9/21 (26) Cbs, Ahcy, Ggt1, Mat2a, Ahcyl1, Papss1, Mat2b, Mars2, Sephs2
TRYPTOPHAN METABOLISM 0.065 9/23 (40) Inmt, Acat1, Haao, Ehhadh, Afmid, Cat, Aldh3a2, Gcdh, Kmo
LYSINE DEGRADATION 0.069 8/34 (64) Acat1, Aass, Ehhadh, Pipox, Plod2, Aldh3a2, Plod3, Gcdh
SYSTEMIC LUPUS ERYTHEMATOSUS 0.071 19/56 (140)
C8a, C8g, Hist1h4h, Hist1h4i, Hist1h4a, Hist1h4f, Hist1h4j, 
Hist1h2be, Hist1h2bn, Hist1h2bk, Hist1h4k, Hist1h2bj, Hist1h2bm, 
Hist1h2bc, Hist1h2bh, Fcgr2b, Hist1h2bf, C4b, C4a
Table 4. List of the top 10 KEGG pathways up- and down-regulated in 1 month-old male TgUmodC147W mice 
relative to age- and sex-matched TgUmodwt. FDR, False Discovery Rate. Number of genes, A/B (C): A, number of 
genes contributing to pathway enrichment; B, number of genes from the KEGG pathway expressed in analysed 
experimental groups; C, total number of genes listed in the KEGG pathway.
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Figure 3. Renal transcript levels of genes belonging to inflammation (upper panel), fibrosis (middle panel) and 
lipid metabolism (lower panel) pathways, as detected by real-time RT-qPCR in 1 month-old male or female 
TgUmodC147W mice. Gene expression is reported as relative to age- and sex-matched TgUmodwt mice (n = 5/group). 
Data are expressed as mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired t-test).
Figure 4. Characterization of infiltrating cells in kidneys of TgUmodC147W mice at 1 month of age. (a) Analysis 
by RT-qPCR of the expression of markers of infiltrating cells in male (upper panel) or female (bottom panel) 
TgUmodC147W mice relative to age- and sex-matched TgUmodwt mice (n = 5/group). Cd45 (Ptprc, common leukocyte 
marker), Cd68 (macrophage), Cd15 (Fut4, granulocyte) transcripts were highly expressed, while Cd5 (T cells) 
and Cd19 (B cells) were barely detectable (data not shown). Data are expressed as mean ± s.e.m. *P < 0.05; 
**P < 0.01; ***P < 0.001 (unpaired t-test). (b) Representative immunohistochemistry (IHC) staining for 
macrophage marker F4/80 in kidneys of TgUmodC147W and TgUmodwt mice. IHC analysis shows focal increase 
(arrowhead) of macrophage infiltrate in TgUmodC147W mice (scale bar 100 µm).
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develops a chronic renal disease34. Although partial, our data also indicate that inflammation in Umod mutant 
mice precedes development of fibrosis. Indeed, transcript levels of Tgfb, a key factor regulating the fibrotic process 
that is found up-regulated in virtually any type of CKD in human and mouse models40, Vim, Col6a1 and Acta2 
are identical in mutant and wild type transgenic mice at one week of age. Similarly to TgUmodC147W mice, inflam-
mation preceding fibrosis was also described in several mouse models of induced renal damage41. Overall, these 
data suggest that inflammation could be a target of future pharmacological intervention directed at treatment of 
the pathology.
Early development of inflammation is coupled with tubular damage, as demonstrated by increased expres-
sion of Lcn2 in kidneys from TgUmodC147W mice at p8. Lipocalin-2 transcript remains at high levels in adult mice, 
and it results as one of the most up-regulated DEGs in our transcriptome analysis. Lipocalin-2 is an established 
marker of distal tubule damage42 that regulates progression of CKD and cyst formation43. It was found to be 
highly up-regulated in renal tissues of other genetic models of progressive kidney damage44. Havcr1, a marker 
of proximal tubular damage45, is found to be up-regulated in adult TgUmodC147W mice used for the transcriptional 
analysis while is identical to TgUmodwt mice at p8. These results might indicate that tubular damage takes place in 
distal tubules, where uromodulin is expressed and then propagates to proximal tubules, possibly via a cross-talk 
between TAL and proximal tubular segments.
Starting from 8 days after birth, we also identified in kidneys of TgUmodC147W mice up-regulation of tran-
scriptional repressor Atf3 that remains at high levels in adult animals. ATF3 belongs to the activating tran-
scription factor/cAMP responsive element-binding protein (ATF/CREB) family. It can be activated by several 
stimuli, including ER stress and unfolded protein response (UPR), chemokines and cytokines, genotoxic and 
cytotoxic agents. ATF3 plays a protective role after renal ischemic injury31, 46, 47 through anti-inflammatory and 
anti-apoptotic effects on epithelial cells46. The anti-inflammatory effect of ATF3 is thought to be exerted via chro-
matin remodelling and subsequent transcriptional inhibition of gene targets of NF-kB pathway46, 48. In TgUmodC147W 
mice Atf3 is specifically induced in the nuclei of TAL cells, likely exerting a protective role in mutant mouse kid-
neys. Given the primary effect of uromodulin mutation, it is likely that Atf3 is induced in TAL cells because of 
ER stress. Indeed, mutations in UMOD leading to protein misfolding and accumulation in the ER likely elicit ER 
and oxidative stress pathways that play a main role in the disease pathogenesis. Evidence for UPR induction in 
TgUmodC147W mice is limited in our dataset, as it was identified only in the group of male mutant mice (Reactome 
database, Unfolded_Protein_Response, ATF4 and PERK, data not shown). This is likely due to the fact that such 
Figure 5. KEGG pathways enriched during the progression of renal disease in TgUmodC147W identified by 
clusterProfiler Bioconductor package. The analysed list is composed of genes that are significantly up- or 
down-regulated in TgUmodC147W female mice at 2 months of age, regardless of their fold change, and that are 
not differentially expressed at 1 month of age in sex-matched mice. Pathways up-regulated are represented by 
red bars while the down-regulated are green. The height of bars is proportional to the statistical significance of 
the term (dotted line corresponds to enrichment P value = 0.05). Fold enrichment of the significant terms is 
represented as a blue line. Fold enrichment is defined as the ratio gene frequency/background frequency (see 
Methods for details).
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cell stress pathways are expected to be increased in TAL cells only. The use of RNA from total kidneys may 
have masked their induction due to a dilution effect. Nevertheless, very recent data indicate UPR induction28, 49  
and derangement of mitochondria49 in TAL segments of ADTKD-UMOD mouse models.
The induction of UPR could also be upstream of inflammation, and the coupling of these responses in special-
ized cells and tissues is now thought to be fundamental in the pathogenesis of inflammatory diseases50. In kidneys 
from p8 mutant mice we identified increased expression of Ccl5 (Rantes) and Ccl12 (MCP-5), that is a structural 
and functional homologue of the human CCL2 (MCP-1)51. Further studies will be need to assess if these chemok-
ines are produced by TAL epithelial cells, possibly downstream of ER stress signals, and play a role in the onset 
and progression of tubulointerstitial disease52.
In conclusion, our study identifies renal induction of inflammatory signals as an early event in the pathogen-
esis of ADTKD-UMOD. Further characterisation of these pathways is warranted to assess their relevance in the 
disease and as potential targets of novel therapeutic intervention.
Figure 6. ER retention of mutant uromodulin in young TgUmodC147W mice. (a) Immunofluorescence analysis for 
transgenic uromodulin (HA) and the ER marker calreticulin in TgUmodwt (upper panel) and TgUmodC147W (lower 
panel) mice at p8. Wild-type transgenic uromodulin is enriched at the apical plasma membrane of TAL cells, 
while most of the transgenic mutant protein is retained in the ER (scale bar 15 µm). (b) ER retention of mutant 
uromodulin is also evident in Western blot experiment, in which samples from TgUmodC147W kidneys show a 
more intense signal for the lower molecular weight uromodulin isoform, corresponding to the protein ER 
precursor. The figure shows cropped blots (full blots are reported in Supplementary Figure 6).
Figure 7. Expression level detected by RT-qPCR of genes involved in pathways of inflammation, fibrosis and 
lipid metabolism in kidneys of TgUmodC147W mice at p8 relative to age- and sex-matched TgUmodwt mice (n = 8 
TgUmodwt and 6 TgUmodC147W). Data are expressed as mean ± s.e.m. **P < 0.01; ***P < 0.001 (unpaired t-test).
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Materials and Methods
Transgenic mice. A detailed description of the methods for the generation of TgUmodC147W and TgUmodwt lines 
was previously reported25. Both mutant (Cys147Trp) and wild type transgenes comprise a 2.9 Kb fragment of the 
mouse Umod gene promoter, non-coding exon 1, intron 1, the coding sequence from exon 2 to 11 and the entire 
3′ UTR. An HA-tag was inserted at the uromodulin N-terminus after the leader peptide. Full constructs were 
injected in FVB mouse. All animal procedures were carried out at San Raffaele Scientific Institute, Milan, Italy, 
according to, and approved by, the San Raffaele Institutional Animal Care and Use Committee (IACUC 571). All 
animal studies were performed in adherence to the Guide for the Care and Use of Laboratory Animals as published 
by the US National Institutes of Health.
Tissue collection and preparation. To collect renal tissues, mice were sacrificed by decapitation after 
anaesthesia with avertin. Kidneys were taken and immediately homogenized in TRIzol reagent (Invitrogen, 
Thermo Fisher Scientific, Waltham, MA) for RNA extraction or in appropriate lysis buffer for protein extraction. 
Renal tissues were fixed in 4% paraformaldehyde and paraffin-embedded for immunohistochemical and histo-
logical analysis or embedded in killik embedding medium (Bio-Optica, Milan, Italy) for immunofluorescence 
staining.
Microarray Analysis. Total RNA was extracted from whole kidney with TRIzol reagent, quantified using the 
Nanodrop 8000 spectrophotometer (Thermo Fisher Scientific) and qualitatively analysed by agarose gel electro-
phoresis. Extracted RNA was treated with DNase (Qiagen, Hilden, Germany) and purified using RNeasy Mini 
Kit columns (Qiagen), according to the manufacture’s protocol. Four animals for each experimental group were 
analysed.
Figure 8. Inflammatory cell infiltrate in the kidneys of p8 TgUmodC147W mice. (a) Analysis by RT-qPCR of 
markers of infiltrating cells in TgUmodC147W mice relative to age- and sex-matched TgUmodwt mice (n = 8 TgUmodwt 
and 6 TgUmodC147W). As in mice at 1 month of age, Cd5 (T cells) and Cd19 (B cells) are barely detectable (data 
not shown). Inflammatory infiltrating cells in the kidneys of TgUmodC147W mice are essentially represented by 
macrophages (Cd68). Data are expressed as mean ± s.e.m. **P < 0.01; ***P < 0.001 (unpaired t-test). (b) 
Representative images of immunofluorescence staining for macrophage marker (F4/80) in kidneys from 
TgUmodwt and TgUmodC147W mice at p8 (scale bar 50 µm). (c) Quantification of F4/80 positive area. Data are 
expressed as mean ± s.d. (n = 4 TgUmodwt and 5 TgUmodC147W). **P < 0.01 (unpaired t-test).
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Transcriptional profiles were determined by using the MouseWG-6 v2.0 Expression BeadChip (Illumina, 
San Diego, CA). Each BeadChip can process simultaneously six samples, each one investigated for a total of 
48,804 transcripts, of which 35,967 are based on the National Center for Biotechnology Information RefSeq 
database (Release 22) and 12,837 are based on UniGene database (Build 199). Total RNA (500 ng) was reverse 
transcribed into cRNA and biotin-UTP labelled using the Illumina TotalPrep RNA Amplification Kit (Applied 
Biosystems, Thermo Fisher Scientific) according to the manufacturer’s protocol. The cRNA was quantified with 
Nanodrop 8000 Spectrophotometer and its quality was evaluated with RNA 6000 NanoChip on the Bioanalyzer 
2100 (Agilent Technologies, Santa Clara, CA). cRNA (1,500 ng) was then hybridized to the BeadChip Array 
and stained with streptavidin-Cy3. All procedures were performed following the manufacturer’s instructions. 
BeadChips have been imaged using the IlluminaBeadArray Reader, a two-channel 0.8-μm-resolution confocal 
laser scanner, and the Illumina BeadScan software. The software IlluminaGenomeStudio v.2011.1 was used to 
elaborate the fluorescence signal to a value whose intensity corresponds to the quantity of the respective tran-
script in the original sample. The same software was used to assess quality controls, including the biological spec-
imen control, hybridization controls, signal generation controls, and negative controls. All quality controls were 
satisfactory. Raw data from the SampleProbeProfile txt file were exported from GenomeStudio software. Gene 
expression data were normalized using the cubic spline algorithm implemented in the Illumina® GenomeStudio 
software. An initial selection of “expressed” probes was done by filtering on the “detection P value” parameter. 
Transcripts with an intensity value significantly different from that of the background (detection P value < 0.01) 
in at least one sample of an analysed series (i.e. experimental groups taken into consideration) were consid-
ered “expressed” genes. Transcriptome data reported in this publication have been deposited in NCBI’s Gene 
Figure 9. Expression of tubular damage and cell stress markers in the kidneys of p8 transgenic mice. (a) 
Expression level (RT-qPCR) of markers of distal tubular damage (Lcn2), of proximal tubular damage (Kim1) 
and of cellular stress (Atf3) in TgUmodC147W mice relative to age- and sex-matched TgUmodwt mice (n = 8 TgUmodwt 
and 6 TgUmodC147W). Data are expressed as mean ± s.e.m. **P < 0.01 (unpaired t-test). (b) Western blot analysis 
showing increased expression of renal Atf3 protein in TgUmodC147W mice (n = 3/group). (c) Representative 
Western blot analysis of kidney lysates from TgUmodwt and TgUmodC147W mice showing expression of Lcn2 (n = 4 
TgUmodwt and 5 TgUmodC147W) and Kim1 (n = 3/group) in TgUmodwt and TgUmodC147W mice (upper panels), and 
relative quantification (bottom panels). Actin was used as a loading control. The figure shows cropped images 
(full blots are reported in Supplementary Figure 6). Data are expressed as mean ± s.d. *P < 0.05 (unpaired 
t-test).
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Expression Omnibus53 and are accessible through GEO Series accession number GSE97093 (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE97093). Subsequent multivariate analyses and differential expression 
were performed on the subset of expressed genes in the groups defined by the experimental design. Principal 
Component Analysis (PCA) was done on expressed genes using scripts in Rstudio54. Hierarchical clustering 
was carried out on the 150 genes showing the greatest inter-group variance among compared groups. Genes 
and samples have been clustered using Euclidean distance and average clustering algorithm (pheatmap; https://
cran.r-project.org/web/packages/pheatmap/index.html). Determination of differentially expressed genes and 
processes was done using LIMMA Bioconductor package55. Pair-wise comparisons (i.e. “contrasts”) were defined 
among the experimental groups considered in a specific design. Benjamini Hochberg multiple comparison cor-
rection was applied to the P value and genes passing a cut-off adjusted P value < 0.05 were considered differen-
tially expressed in the specified comparison. Gene Set Enrichment Analysis (GSEA) (http://www.broadinstitute.
org/gsea/index.jsp), which identifies groups of genes enriched towards the top or bottom of a ranked list of genes 
based on a running sum statistics, was used to identify functionally related groups of genes whose expression 
pattern was correlated with the template, defined by the hallmark curated gene sets from MSigDB56, 57. Pathway 
enrichment analysis was also performed by using DAVID software (https://david.ncifcrf.gov/).
Pathways enriched during the progression of renal disease in TgUmodC147W mice were identified by carrying 
out a biological Term Enrichment Analysis using KEGG Pathways database58 and clusterProfiler Bioconductor 
package59, 60. We compared the prevalence of gene annotations (KEGG Pathways) among differentially expressed 
genes (i.e. significantly up- or down-regulated in TgUmodC147W female mice at 2 months of age, regardless of their 
fold change, and not differentially expressed at 1 month of age in sex-matched mice) to their prevalence in a 
background defined by all the expressed genes (as defined above). Fold enrichment was defined as the ratio gene 
frequency/background frequency (ratio of the number of genes annotated to a given biological term in the list 
of DEGs over the number of DEGs)/(ratio of the number of genes annotated to that biological term in the entire 
background set over the total number of genes in the background set).
Real-time qPCR analysis. Total RNA from mouse whole kidney was extracted by homogenization in 
TRIzol reagent. RNA sample concentrations were determined by using Nonodrop-8000 and RNA quality was 
assessed on agarose gel. For each sample 1 μg of extracted RNA was reverse-transcribed using iScript kit (BioRad 
Laboratories, Hercules, CA) according to the manufacturer’s protocol. Expression of target genes was analysed 
by RT-qPCR on LightCycler 480 (Roche, Basel, Switzerland) using qPCR Core kit for SYBR Assay (Eurogentec, 
Liège, Belgium). Specific primers were designed by using Primer 3 (a list of all primers used in this study is 
reported in Supplementary Table 1) and the amplification efficiency for each couple of primers was determined 
by dilution curves. Expression of genes of interest was normalized to Hprt1. The relative mRNA expression was 
calculated following the ΔΔCT method61.
Immunohistochemistry and histology. Immunohistochemistry was performed on 5 µm-thick kidney 
sections using standard procedures (primary antibodies are listed below) followed by a counterstaining with 
hematoxylin. Routine staining (Periodic acid–Schiff, PAS; Acid Fuchsin Orange G, AFOG), were performed on 
kidney slices (5 µm-thick) according to standard protocols. For both immunohistochemistry and histological 
analysis, sections were viewed under a Zeiss Axioscope 40FL microscope (Carl Zeiss, Oberkochen, Germany), 
equipped with AxioCam MRc5 digital video camera. Images of kidney slices from TgUmodC147W and TgUmodwt 
mice were recorded using identical parameters with AxioVision software 4.3 (Carl Zeiss). Quantification of 
histological features was performed on stained renal sections by an observer unaware of the mouse genotype. 
Mesangial expansion and mesangial hypercellularity were assessed semiquantitatively (0 = absent; 1 = 1–50%; 
2 = 51–100%). Interstitial inflammation and fibrosis, presence of tubular casts and tubular dilation were 
assessed semiquantitatively (0 = absent; 1 = 1–30%; 2 = 31–60%; 3 = 61–100%). Presence of focal/segmental 
glomerulosclerosis was quantitatively expressed as % of the total number of glomeruli (30 glomeruli for each 
sample).
Immunofluorescence staining. Immunofluorescence was carried out using standard protocol on 7 
µm-thick kidney sections. Briefly, after 1 h in blocking solution, slides were incubated over-night with spe-
cific primary antibody (see below) and then with appropriate AlexaFluor-labeled secondary antibody (Life 
Technologies, Thermo Fisher Scientific). All slides were viewed under a DM 5000B fluorescence upright 
microscope (Leica DFC480 camera, Leica DFC Twain Software, 40X/0.75 lens) (Leica Microsystems, Wetzlar, 
Germany) or under an UltraVIEW ERS spinning disk confocal microscope (UltraVIEW ERS-Imaging 
Suite Software, Zeiss 63X/1.4; PerkinElmer Life and Analytical Sciences Boston, MA). Identical acquisition 
parameters were ensured for the visualization of the same antibody in different kidney sections. All images 
were imported in Photoshop CS (Adobe Systems, Mountain View, CA) and adjusted for brightness and 
contrast.
Western blot analysis. Mouse renal tissues were homogenized on ice immediately after explants in 
the following buffer (to detect transgenic uromodulin and Kim1): NaCl 150 mM, N-octylglucoside 60 mM, 
Protease-Inhibitor Cocktail 1:1,000 (Sigma-Aldrich, St. Louis, MO) and Tris-HCl 20 mM, pH 7.4 or in the fol-
lowing buffer (to detect Atf3 and Lcn2): Urea 8 M, NaCl 500 mM, EDTA 0.1 mM, EGTA 0.1 mM, Nonidet P40 
0.1% (v/v), DTT 1 mM, Protease-Inhibitor Cocktail 1:1,000 (Sigma-Aldrich) and HEPES 10 mM, pH 7.9. Protein 
lysates were separated on an 8% (transgenic uromodulin and Kim1) or 12% (Atf3 and Lcn2) SDS-PAGE gel in 
reducing condition and transferred onto nitrocellulose membrane (GE Healthcare, Chicago, IL). Immunoblot 
was performed following standard protocols. Quantification of the optical band densities was performed using 
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the gel analysis option of ImageJ software62. The optical density of proteins of interest was normalized to the one 
of β-Actin or Gapdh (loading controls) run on the same gel.
Antibodies. The following antibodies were used for immunohistochemical, immunofluorescence and 
Western blot analyses: sheep polyclonal antibody against uromodulin (ab9029, Abcam, Cambridge, UK) (1:200 
for IF and for IHC); rat monoclonal antibody against HA (#11 867 423 001, Roche) (1:500 for IF and 1:1,000 for 
WB); rabbit polyclonal antibody against calreticulin (C4606, Sigma-Aldrich) (1:500 for IF); rat antibody against 
mouse F4/80 (MCA497GA, Serotec, BioRad)(1:50 for IF and IHC); rabbit polyclonal antibody against Atf3 (sc-
188, Santa Cruz Biotechnology, Dallas, TX) (1:50 for IF and 1:500 for WB); goat polyclonal against Lipocalin 2/
NGAL (AF1857, R & D Systems, Bio-Techne, Minneapolis, MN) (1:500 for WB); rabbit polyclonal against Kim1 
(TIM-1) (NBP1-76701, Novus Biologicals, Bio-Techne) (1:500 for WB); mouse monoclonal antibody against 
β-Actin (A2228, Sigma-Aldrich) (1:20,000 for WB); mouse monoclonal antibody against Gapdh (sc-32233, Santa 
Cruz Biotechnology) (1:20,000 for WB).
Statistical analysis. Data are means ± standard deviation (s.d.) or standard error of mean (s.e.m.). 
Comparisons between groups were performed using two-tailed unpaired Student’s t-test, or two-tailed 
non-parametric Mann-Whitney test. Significance level was set to P < 0.05.
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